PHM321 Questions and Correct Answers/
Latest Update / Already Graded
Manufacturer of Bayfortus
Ans: AstraZeneca & Sanofi
MOA Beyfortus
Ans: binds F protein on RSV - preventing virus fusion
Indication for Beyfortus
Ans: Infants and Neonates in 1st RSV season
Infants with high risk in 2nd RSV season
Is Beyfortus Rare disease?
Ans: no its common
Administration of Beyfortus
Ans: IM by HCP
Competitors for Beyfortus
All rights reserved © 2025/ 2026 |
, Page |2
Ans: Palivizumab
Unmet need for Beyfortus
Ans: no current treatment for RSV
Reimbursement for Beyfortus
Ans: NOC by HC
CADTH and INESS - under review
Camzyos Manufacturer
Ans: Bristol-myers-squibb
Camzyos MOA
Ans: reversible inhibitor of cardiac myosin ATPase
reduces actin-myosin cross- bridges
Camzyos Indication
Ans: Symptomatic obstructive hypertrophic cardiomyopathy
adults with NYHA stage 2 to 3 heart failure
All rights reserved © 2025/ 2026 |